

October 19, 2012

## **ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2013 Financial Results**

WALTHAM, Mass.--(BUSINESS WIRE)-- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 26, 2012, to discuss ImmunoGen's financial results for the three-month period ended September 30, 2012 — the first quarter of the Company's 2013 fiscal year. Management also will provide an update on the Company and more information about the economic terms of the trastuzumab emtansine (T-DM1)-related license with Genentech, a member of the Roche Group.

To access the live call by phone, dial 913-312-1472. Passcode: 4483380. The call also may be accessed through the Investor Information section of the Company's website, [www.immunogen.com](http://www.immunogen.com). Following the live webcast, a replay of the call will be available at the same location through November 9, 2012.

### **About ImmunoGen, Inc.**

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-killing agents specifically to tumor cells. There are now ten TAP compounds in clinical development, of which three are wholly owned by the Company. Marketing applications for trastuzumab emtansine (T-DM1), the most advanced compound using ImmunoGen's TAP technology, have been submitted in the US and Europe. Roche is developing this compound globally under an agreement between ImmunoGen and Genentech, a member of the Roche Group. More information about ImmunoGen can be found at [www.immunogen.com](http://www.immunogen.com).

#### Investors:

ImmunoGen, Inc.

Carol Hausner, 781-895-0600

Executive Director, Investor Relations and Corporate Communications

[info@immunogen.com](mailto:info@immunogen.com)

or

Media:

The Yates Network

Barbara Yates, 781-258-6153

Source: ImmunoGen, Inc.

News Provided by Acquire Media